Patsoukis, N., Duke-Cohan, J.S., Chaudhri, A., Aksoylar, H.-I., Wang, Q., Council, A., Berg, A., Freeman, G.J. and Boussiotis, V.A. (2020a). Interaction of SHP-2 SH2 domains with PD-1 ITSM induces PD-1 dimerization and SHP-2 activation. Communications Biology, 3(1). doi:10.1038/s42003-020-0845-0. Available at: /resources/interaction-of-shp-2-sh2-domains-with-pd-1.pdf [Accessed 17 Oct. 2022].
Patsoukis, N., Wang, Q., Strauss, L. and Boussiotis, V.A. (2020b). Revisiting the PD-1 pathway. Science Advances, 6(38), p.eabd2712. doi:10.1126/sciadv.abd2712. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7500922/ [Accessed 17 Oct. 2022].
Pu, Y. and Ji, Q. (2022). Tumor-Associated Macrophages Regulate PD-1/PD-L1 Immunosuppression. Frontiers in Immunology, 13. doi:10.3389/fimmu.2022.874589. Available at: /resources/tumor-associated-macrophages-regulate-pd-1-pd-l1-immunosuppression.pdf [Accessed 17 Oct. 2022].
Robert, C. (2020). A decade of immune-checkpoint inhibitors in cancer therapy. Nature Communications, 11(1). doi:10.1038/s41467-020-17670-y. Available at: /resources/immune-checkpoint-cancer-therapy.pdf [Accessed 17 Oct. 2022].
Sánchez-Magraner, L., Miles, J., Baker, C.L., Applebee, C.J., Lee, D.-J., Elsheikh, S., Lashin, S., Withers, K., Watts, A.G., Parry, R., Edmead, C., Lopez, J.I., Mehta, R., Italiano, A., Ward, S.G., Parker, P.J. and Larijani, B. (2020). High PD-1/PD-L1 Checkpoint Interaction Infers Tumor Selection and Therapeutic Sensitivity to Anti-PD-1/PD-L1 Treatment. Cancer Research, 80(19), pp.4244–4257. doi:10.1158/0008-5472.can-20-1117. Available at: /resources/pd-1-pd-l1-checkpoint-interaction.pdf [Accessed 17 Oct. 2022].